KOD ▲ +3.7% - Kodiak Sciences Inc. $KOD Kodiak Sciences (KOD) said it will report topline results from its Phase 3 DAYBREAK study on Monday, September 28, 2026, and hold a webcast at 8:30 a.m. Eastern. • Study focus: DAYBREAK evaluates two Kodiak treatment candidates in patients with wet age-related macular degeneration, also known as wet AMD. • First candidate: Zenkuda, or tarcocimab tedromer, is one of the treatments being evaluated in the Phase 3 study. • Second candidate: KSI-501, or tabirafusp alfa tedromer, is the other treatment being evaluated. 26-SEP-2026 08:19 AM ET